Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

Trial Details

NCT ID
NCT06375044
Phase
PHASE1
Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • SIM0500
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Orange, California, United States|33.78779,-117.85311
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Voluntary participation and signature of informed consent form.
  • ≥18 years of age.
  • Have documented diagnosis of relapsed or refractory multiple myeloma according to Criteria for Response to Multiple Myeloma Treatment(IMWG)diagnost…
  • Life expectancy ≥12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →